[HCV-HBV infection].

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis C (HCV) and hepatitis B (HBV) infections are major causes of viral hepatitis.
• These chronic viral infections increase the risk of liver cirrhosis and hepatocellular carcinoma.
• Effective treatment is crucial to manage viral hepatitis and prevent severe liver complications.

Purpose of the Study:

• To review the efficacy of interferon (IFN)-based therapies for chronic viral hepatitis.
• To highlight the benefits of combination therapy for HCV and IFN therapy for HBV.
• To discuss the impact of these treatments on viral suppression and long-term outcomes.

Main Methods:

• Review of existing clinical reports and therapeutic guidelines.
• Analysis of sustained viral response rates for HCV treatment.
• Evaluation of HBeAg seroconversion rates for HBV treatment.

Main Results:

• Combination therapy with pegylated interferon alpha-2b and ribavirin achieves approximately 50% sustained viral response in chronic HCV after 48 weeks.
• Long-term interferon therapy for HCV has been associated with a reduced risk of liver carcinogenesis.
• Twenty-four weeks of interferon therapy for chronic HBV results in approximately 30% HBeAg seroconversion rates, suppressing viral replication.

Conclusions:

• Interferon-based therapies are effective in managing chronic viral hepatitis.
• Combination therapy offers significant benefits for HCV patients, including sustained viral response.
• IFN therapy for HBV aids in viral suppression and attenuates hepatitis, reducing long-term risks.